Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis.

McMaster University, Hamilton, Ontario, Canada.
The Canadian Journal of Urology (Impact Factor: 0.91). 02/2013; 20(1):6607-14.
Source: PubMed

ABSTRACT Urinary tract infections (UTIs) are the most common infections affecting women, and often recur. Lactobacillus probiotics could potentially replace low dose, long term antibiotics as a safer prophylactic for recurrent UTI (rUTI). This systematic review and meta-analysis was performed to compile the results of existing randomized clinical trials (RCTs) to determine the efficacy of probiotic Lactobacillus species in preventing rUTI.
MEDLINE and EMBASE were searched from inception to July 2012 for RCTs using a Lactobacillus prophylactic against rUTI in premenopausal adult women. A random-effects model meta-analysis was performed using a pooled risk ratio, comparing incidence of rUTI in patients receiving Lactobacillus to control.
Data from 294 patients across five studies were included. There was no statistically significant difference in the risk for rUTI in patients receiving Lactobacillus versus controls, as indicated by the pooled risk ratio of 0.85 (95% confidence interval of 0.58-1.25, p = 0.41). A sensitivity analysis was performed, excluding studies using ineffective strains and studies testing for safety. Data from 127 patients in two studies were included. A statistically significant decrease in rUTI was found in patients given Lactobacillus, denoted by the pooled risk ratio of 0.51 (95% confidence interval 0.26-0.99, p = 0.05) with no statistical heterogeneity (I2 = 0%).
Probiotic strains of Lactobacillus are safe and effective in preventing rUTI in adult women. However, more RCTs are required before a definitive recommendation can be made since the patient population contributing data to this meta-analysis was small.

  • Source
    Food Science and Human Wellness. 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Urinary tract infection is a common problem among patients with neurogenic bladder dysfunction that can be costly and challenging to manage. Current literature on the topic of preventing urinary tract infections in this heterogeneous patient population is challenged by the difficulty in defining urinary tract infections and by the lack of long-term data from controlled randomized studies. New research suggests that intradetrusor injection of onabotulinumtoxin A may be a useful adjunct in preventing urinary tract infections, and further studies are needed to determine if probiotics, bacterial interference, and/or vaccines will prove to be of use in the population.
    Current Bladder Dysfunction Reports 12/2014; 9(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The child with lower urinary tract symptoms, in the absence of neurological abnormalities, represents an increasingly common source of referral to the pediatric urologist. Patients with lower urinary tract dysfunction are at increased risk of urinary tract infections (UTIs), which can be a potential source of expense, inconvenience, and even morbidity and renal impairment. Many of these patients present with concomitant bowel dysfunction in the form of constipation and encopresis. As a result, the term “bladder and bowel dysfunction” (BBD) has been introduced and refers to the close relationship of the bladder and bowel and their interrelated disturbances. An in-depth understanding of BBD and its role in recurrent UTI is the key to treatment and prevention of further morbidity in these patients. We present an updated review of the literature on BBD and UTIs in children, including its pathogenesis, evaluation, and management.
    Current Bladder Dysfunction Reports 09/2014; 9(3):188-196.


Available from
May 26, 2014